What does the UK’s preferred medtech regulatory system look like after Brexit, whenever that may take place? That was the question being tackled at the first of probably several meetings on “Medical Device Regulation in a Post-Brexit Landscape,” under the auspices of the UK's All-Party Parliamentary Group (APPG) on Access to Medicines and Medical Devices on 24 October.
Gary Slack, senior VP of medical devices at UK notified body BSI, was clear that the UK should not diverge...
Welcome to Medtech Insight
Create an account to read this article
Already a subscriber?